Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.

Emily R Hankosky, Hui Wang,Lisa M Neff,Hong Kan,Fangyu Wang,Nadia N Ahmad,Adam Stefanski,W Timothy Garvey

Diabetes, obesity & metabolism（2023）

引用 0|浏览2

暂无评分

摘要

Tirzepatide treatment significantly reduced the 10-year predicted risk of developing T2D compared with placebo in participants with obesity or overweight, regardless of baseline glycaemic status.

查看译文

关键词

anti-medications, obesity, prediabetes, risk prediction, tirzepatide, type 2 diabetes

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要